Bernstein Analyst has Doubts About Potential 'Compendia Listing' for Bristol-Myers' (BMY) Opdivo
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Bristol-Myers Squibb Co. (NYSE: BMY) declined Friday morning following comments in a research note from Bernstein analyst Tim Anderson. Until recently, he thought the company's Opdivo had a good chance of getting an off label listing for pending subgroup analyses of its failed Checkmate-026 trial. However, Anderson said his "view on this has changed."
The analyst explained, "In our recent prior reports, we have claimed that BMY would still likely get a 'compendia listing' for Opdivo based on the pending subgroup analysis from the failed Checkmate-026 trial, under the assumption that 'high expressers' of the PDL1 biomarker would still show efficacy (matchingwhat MRK showed in Keynote-024). This is important because compendia listings help gate reimbursement in the US. By law, Medicare has to follow compendia recommendations (and most lung cancer patients are Medicare patientsgiven their age at diagnosis). Private payers often do the same (although they are not required to by law),"
Anderson added, "However, our updated view on this has shifted based on our due diligence and our discussion with BMY. Specifically, we are less certain BMY will get a compendia listing, even if subgroup analyses are positive. We are unable to identify many precedent cases where a phase 3 trial failed, yet compendia listing was granted. Further, because BMY's analysis of high expressers is “exploratory” (vs. "pre-specified") the robustness of the analysis will be less. Also, because MRK’s Keytruda will be labeled for high expressers of PDL1, it is difficult to say an unmet medical need in this patient segment exists that would encouragea compendia listingon exploratory analyses(but this is not an explicit criterion when such decisions are made)."
Anderson concluded, "The bottom line is that even if efficacy is seen in high expressers (which is still what we expect; if this is not the case, investors and experts alike will be baffled), it may not lead to much. Without compendia listing, most payers will likely hesitate to reimburse for Opdivo’s usage as monotherapy in 1L lung. Another item to note: compendia listings are really only a US phenomenon, and outside of the USthere is no similar process that is common."
Bernstein has a Market Perform rating om Bristol-Myers Squibb Co. with a price target of $65.00
Shares of Bristol-Myers Squibb Co. closed at $56.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Active options: AAPL BAC BMY GE FB IBM NFLX C AMZN SWKS TSLA MSFT NVDA
- TransDigm (TDG) Valeant Comparison 'Nothing New', Tweet Risk Low and Would Use Weakness to Buy - Credit Suisse
- Union Pacific (UNP) PT Raised to $102 at Stifel Following 4Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Comments, Trader Talk
Related EntitiesSanford C. Bernstein
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!